- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04799691
Comparison of 2 Ventilatory Support Strategies During Coronavirus Disease 2019 (Covid-19) Pneumonia (STRATIC)
October 10, 2022 updated by: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Comparison of 2 Ventilatory Support Strategies in Patients With Covid-19 Pneumonia Admitted in ICU : Retrospective Monocentric Study
This retrospective monocentric study compares 2 ventilatory support strategies on outcomes (length of stay, intubation, mortality) in patients admitted in Intensive Care Unit with Covid-19 related pneumonia : invasive strategy used during the first period and non-invasive strategies (Continuous Positive Airway Pressure, High Flow Nasal Canula, Prone Position) used during the second period.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
133
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Var
-
Toulon, Var, France, 83056
- Hôpital Sainte Musse
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with COVID 19 acute hypoxemic respiratory failure admitted in Hospital Sainte Musse ICU in 2020
Description
Inclusion Criteria:
- Patient with confirmed SARS COV2 infection
- Acute Respiratory Distress Syndrome
- Patient more than 18 year old
Exclusion Criteria:
- Intensive Care Unit admission for extra pulmonary failure
- "Do Not Reanimated" order
- Patient from another Intensive Care Unit
- Patient objection
- Judicial protection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Invasive strategy group
Patients admitted in ICU with Covid-19 related pneumonia during COVID19 first period.
|
Use of an invasive ventilatory support strategy
|
|
Non-invasive strategy group
Patients admitted in ICU with Covid-19 related pneumonia during COVID19 second period.
|
Use of non-invasive ventilatory support strategies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of stay in ICU
Time Frame: At the moment of ICU discharge or death, up to 3 month
|
Number of days spent in ICU
|
At the moment of ICU discharge or death, up to 3 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: At the moment of ICU discharge or death, up to 3 month
|
Rate of patients alive at the moment of intensive care unit discharge
|
At the moment of ICU discharge or death, up to 3 month
|
|
Complications
Time Frame: At the moment of ICU discharge or death, up to 3 month
|
Number of complications during intensive care unit stay
|
At the moment of ICU discharge or death, up to 3 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Aude Garnero, MD, Centre Hospitalier Intercommunal Toulon La Seyne sur Mer
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2021
Primary Completion (Actual)
January 15, 2022
Study Completion (Actual)
January 15, 2022
Study Registration Dates
First Submitted
March 15, 2021
First Submitted That Met QC Criteria
March 15, 2021
First Posted (Actual)
March 16, 2021
Study Record Updates
Last Update Posted (Actual)
October 12, 2022
Last Update Submitted That Met QC Criteria
October 10, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-CHITS-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
PfizerActive, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionUnited States
-
Shanghai Public Health Clinical CenterNot yet recruiting
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)Germany
-
PfizerRecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 InfectionBelgium
-
ModeX Therapeutics, An OPKO Health CompanyRecruitingCOVID -19 | COVID-19 (Prevention)United States
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID ConditionCanada
-
RSUP PersahabatanCompletedPost COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID Syndrome Long CovidIndonesia
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
Clinical Trials on Invasive ventilation strategy
-
Oslo University HospitalRigshospitalet, Denmark; Aalborg University HospitalNot yet recruitingAcute Respiratory Distress Syndrome (ARDS) | Acute Hypoxemic Respiratory Failure
-
Affiliated Hospital of Nantong UniversityCompletedTumor MicroenvironmentChina
-
Rui WangCompletedRespiratory Distress Syndrome, AdultChina
-
Azienda Ospedaliero Universitaria Maggiore della...CompletedSurgery | Atelectasis | Artificial RespirationItaly
-
Shanghai Zhongshan HospitalNot yet recruitingST-segment Elevation Myocardial Infarction (STEMI)
-
University Hospital, MontpellierRecruiting
-
University Hospital, AngersCompleted
-
University Hospital, AngersCompletedAcute Lung Injury | ARDS (Acute Respiratory Distress Syndrome) | Positive End Expiratory Pressure (PEEP) | Electrical Impedance Tomography (EIT)France
-
University of California, San DiegoCompletedAcute Lung Injury | Chronic Thromboembolic Pulmonary HypertensionUnited States
-
Beth Israel Deaconess Medical CenterCompletedAcute Respiratory Distress SyndromeUnited States